Alan Nurden Shares A Study on Unusual Form of Glanzmann Thrombasthenia
Alan Nurden, Emeritus Research Director at CNRS, shared on LinkedIn:
”A detailed review of published cases of an unusual form of Glanzmann thrombasthenia where gain-of-function mutations in ITGA2B/ITGB3 genes are linked to dysregulation of RhoA activity in megakaryocytes and cytoskeletal-mediated changes in proplatelet formation and platelet release.
Such cases offer a rare insight into integrin biology.”
Read the full article here.
Article: ITGA2B/ITGB3-Related Macrothrombocytopenia Associated With Gain-of-Function Mutations in ITGA2B or ITGB3 Genes
Authors: Jiao Wu, Han Yan, Zijian Li, Yilin Zhu, Ruonan Shao, Honglei Xin, Tongyu Jia, Mengyu Ge, Lu Zhang, Suyu Jiang, Jianhua Mao, Jiansong Huang, Chao Fang, Xiaodong Xi, Xiaofeng Shi
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery